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1. List of abbreviations 
AIDS Acquired Immune Deficiency Syndrome 
ART antiretroviral therapy 
3ART patients treated with a conventional 3-drug ART 
Bregs regulatory B cells 
CD cluster of differentiation 
CHI chronic HIV infection 
CNS central nervous system 
CO controllers 
CTLA-4 cytotoxic T lymphocyte antigen-4 
DNA Deoxyribonucleic acid 
EC elite controllers 
HC HIV-uninfected controls/ healthy controls 
HIV Human Immunodeficiency Virus 
IFN- γ Interferon γ 
IIT investigator initiated trial 
IL-2 Interleukin-2 
LAG-3 lymphocyte-activation gene 3 
M-MDSCs monocytic myeloid-derived suppressor cells 
MIP-1β macrophage inflammatory protein-1β 
NE New Era  
OI opportunistic infection 
ON overnight  
PBMCs peripheral blood mononuclear cells 
PD-1 programmed death-1 
2 
PHI primary HIV infection 
PMN-MDSCs polymorphonuclear myeloid-derived suppressor cells 
PR progressors 
RNA ribonucleic acid 
SIV Simian Immunodeficiency Virus 
TIM-3 T cell immunoglobulin and mucin domain containing protein-3 
TNF-α tumor necrosis factor α 
Tregs regulatory T cells 
ÜN über Nacht 
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3.1. Human Immunodeficiency Virus (HIV) infection 
3.1.1. Epidemiology of HIV infection 
In Germany, approximately 88.400 people were living with HIV at the end of 
2016. 86% of diagnosed patients are being treated with antiretroviral therapy 
(ART). Approximately 460 patients died because of their HIV infections in 2016 
(1, 2).  
Globally, the numbers are even more alarming: 36.7 million people were living 
with HIV worldwide in 2016 and only 53% (20.9 million people) had access to 
antiretroviral therapy (ART) in June 2017 (3). And yet, the latest number of 
treated patients signifies a 1.2-fold increase compared to 2015 and even 2.7-
fold compared to 2010. This raise contributes to an encouraging 48% decline of 
AIDS related deaths from 1.9 million in 2005 to one million in 2016 (the lowest 
number since 2000) (4).   
In the last decades, intense research efforts resulted in an ART with a low pill 
burden and few side effects. Today, ART is highly efficacious in terms of 
suppressing viral load and decreasing mortality. Therefore, life expectancy of 
young treated HIV patients in Europe and North America increased massively in 
the last two decades and is now comparable to healthy adults (5). Nevertheless, 
due to highly efficient resistance mechanisms of the HI virus and 47% HIV-
infected patients who do not have access to treatment, there is an urgent need 
for alternative treatment strategies towards a sterilizing cure (eradication of 
virus) or at least a functional cure (sustained immune control of HIV-1 viremia). 
3.1.2. Pathogenesis of HIV infection 
For entry and spreading within the human immune system, the HI virus uses the 
CD4 T cell marker along with chemokine coreceptors (CCR5 and CXCR4 
respectively). With CD4 T lymphocytes, dendritic cells, macrophages, central 
nervous system (CNS) microglia cells expressing these receptors, HIV is able to 
infect these cells and, thus, to replicate in blood cells, lymphatic organs and 
CNS. After infection, viral load peaks with often several million copies per ml 
blood. Over the course of the disease, cytotoxic CD8 T cells of the adaptive 
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immune system among others are activated to eradicate HIV-infected cells 
resulting in the decrease of the viral load and the plateau at a certain individual 
level which predicts the rate of disease progression as the so-called “viral 
setpoint” (approximately 2 log10 copies/ml less than the peak) (6, 7). In the 
following years, HIV disease persists in a clinically asymptomatic stage. The 
duration varies due to the age of the patient, the pathogenicity of the virus, or 
environmental factors. The latent phase lasts for 8 to 10 years but increasingly 
for a shorter period of time (8, 9). The HIV-specific immune response is not able 
to prevent the virus completely from replicating. Without antiviral treatment of 
the patient, the immune system loses the control over viral replication and the 
patient reaches the stage of AIDS. The CD4 T cell count falls below 200/µl, 
pathogens can spread and, therefore, opportunistic infections arise (10, 11). 
 
Figure 1 The natural course of HIV infection (diagram adapted to (7, 11)). In the first weeks after viral infection, the viral 
load increases tremendously (more than 6 log10 copies/ml, median 6.7 log10 copies/ml (7)) and the number of CD4 T 
lymphocytes decreases. After CD8 T cell activation, the viral set point is reached (approximately minus 2 logs compared 
to peak (7)), the viral RNA decreases and plateaus for about 8 to 10 years (latent phase of infection). Without ART AIDS 
develops. PHI = primary HIV infection, CHI = chronic HIV infection, OI = opportunistic infection, RNA = ribonucleic acid. 
However, even in the absence of ART, a certain group of patients – the so-
called controllers – can control viremia below 2000 copies/ml spontaneously. 
Less than 1% of untreated infected patients (“elite controllers”) even suppress 
7 
viral loads below 50 copies/ml. The reasons for this singular ability of controllers 
are not completely clarified, however, there is evidence that immunological CTL 
defense and restrictions in HLA allele may play a crucial role (6, 12-15). 
3.1.3. Antiretroviral therapy (ART) 
National and international treatment guidelines recommend a therapy regimen 
containing three compounds (two different classes of antiretroviral drugs) to 
interfere substantially with the viral replication cycle (16-18). With conventional 
3-drug ART (3ART) a durable suppression of the HI virus below detection limit 
(state of the art: <20 copies/ml) is possible but ART cannot wipe out latent virus 
in resting T cells. Proviral HIV DNA is harbored in quiescent CD4 T cells 
(central memory and transitional memory) building the latent reservoir. Thus, 
viral eradication using the currently available antiretroviral drugs cannot be 
achieved (19-22).  
After treatment interruption, the virus restarts to replicate and viral load 
increases (23-25). However, a reduction of reservoir has been shown if ART 
was early started in primary HIV infection (PHI) (26, 27). Therefore, treatment 
strategies were contrived to analyze the impact of early treatment in acute 
infection as well as with treatment intensification. One of them, the Visconti 
(Viro-Immunological Sustained CONtrol after Treatment Interruption) study, 
analyzed the influence of ART in 14 individuals who started very early in PHI 
and controlled viremia for several years after the interruption of the treatment. 
The authors concluded a beneficial effect of an early prolonged ART e.g. 
because of low viral reservoir as well as a low proportion of long-lived CD4 T 
cells (28-30). Furthermore, the New Era study, a German investigator initiated 
trial (IIT) of treatment intensification with the aim of virus eradication, looked at 
the impact of an intensified, 5-drug treatment strategy on residual viremia. Two 
supplementary drug classes (the integrase inhibitor raltegravir and the CCR5 
inhibitor maraviroc) were added to a PI based regimen. Patients started 
intensified treatment in PHI and chronic HIV infection (CHI). The study 
comprised 40 patients with a CD4 nadir above 200 cells/µl and without history 
of AIDS or protease inhibitor (PI) resistance. PHI patients (n = 20) had 
detectable HIV RNA and an early stage of acute infection with less than two 
bands in Western blot analysis. Before starting the 5-drug regimen, CHI patients 
8 
(n = 20) were required to be successfully treated on a stable PI based regimen 
for at least 36 months. All study participants have been on treatment 
intensification for more than 5 years. After 24 months of treatment 
intensification, significantly lower levels of median proviral DNA were observed 
in PHI versus CHI patients (31-33). With more than 5 years of NE regimen, the 
immunological status was to be evaluated before an eventual treatment 
interruption. This was the project for the second manuscript of this dissertation. 
Similar studies to compare treatment intensification and conventional 3-drug 
ART have been performed earlier. However, no differences in viral suppression 
and immune activation have been observed and immune suppressive cells 
were not evaluated (34, 35). 
3.1.4. CD8 T cell response 
Back in the late 1980s, the suppression of viral replication by CD8 T cells was 
first discovered in vitro, closely followed by detecting HIV-specific CD8 T cells in 
HIV-infected patients (36-38). Already in acute HIV infection, these HIV-specific 
CD8 T cells are activated and their levels increase tremendously, resulting in a 
decrease of viral load after the initial peak. In primary HIV infection, the T cell 
response is very strong and effective, forcing the HI virus to develop escape 
mutations for further replication (39-41). This temporal association of increasing 
viral load and activated CD8 T cell response suggests the crucial role of CD8 T 
lymphocytes in recognizing and killing HIV-infected cells (42-50) which was 
additionally confirmed by depletion studies in SIV-infected rhesus macaques 
(51-53). The latter studies showed an increase of viral load in acute and chronic 
SIV infection and even in antiretroviral treated animals after the complete 
depletion of CD8 T cells by a monoclonal antibody. Therefore, HIV-specific CD8 
T cells were identified as crucial for the control of viremia in acute as well as 
chronic infection. 
3.1.5. Immune exhaustion 
After clearing a pathogen during the phase of acute infection, the 
downregulation of the activated immune system is required to prevent 
unspecific autoimmune reactions. The physiological role of inhibitory immune 
signaling is dedicated to reduce the effectivity of T cell lymphocytes e.g. by T 
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cell proliferation, production of cytokines and chemokines. The infection with 
HIV is a chronic disease without clearance by the immune system resulting in a 
chronic, continuous immune activation which is a hallmark of HIV infection. This 
immune activation strongly predicts disease progression, independently of other 
markers of disease progression like CD4 decline or viral load (14, 54-60).  
During the natural course of untreated HIV infection, the CD8 T cell response 
loses effectivity – by decreased proliferation and a decline in the production of 
cytokines and chemokines and, thus, results in disease progression. In contrast 
to untreated patients with progressive HIV infection (progressors), controllers 
and elite controllers maintain CD8 T cells which are still polyfunctional, i.e. 
these cells still have the ability to mobilize CD107a (degranulation), to produce 
the cytokines IL-2, IFN-γ and TNF-α as well as the chemokine MIP-1β (15, 61, 
62).  
The loss of effectivity of CD8 T cells during HIV infection was termed immune 
exhaustion and the reasons for this are not completely understood so far. With 
increasing immune activation, immune inhibitory signals (also called “immune 
checkpoints”) are expressed more and more on CD8 T cells, e.g. programmed 
death-1 (PD-1) (63-66), CTLA-4 (67), LAG-3 (68), and TIM3 (69) (all reviewed 
in (70)). However, just recently, immune inhibitory cells have been described to 
play a decisive role in immune exhaustion. Studying the role of these cells in 
chronic HIV infection is the core of this dissertation. The three main groups are: 
myeloid derived suppressor cells (MDSCs), regulatory T cells (Tregs) and 
regulatory B cells (Bregs). 
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3.2. Immune suppressive cells 
 
 
Figure 2 Development of immune suppressive cells (simplified scheme adapted to (71-75)). Regulatory T cells (Tregs) 
and regulatory B cells (Bregs) develop of lymphatic progenitor cells in thyme and bone marrow respectively. Myeloid-
derived suppressor cells (MDSCs) originate from myeloid cells and, therefore, belong to the innate immune system. All 
three cell types accumulate under certain conditions e.g. in chronic infections, suppress CD8 T lymphocytes and are 
said to be involved in T cell exhaustion. PMN-MDSC = polymorphonuclear MDSC, M-MDSC = monocytic MDSC.  
3.2.1. Myeloid-derived suppressor cells (MDSCs) 
MDSCs comprise a heterogeneous population of immature myeloid cells that 
inhibit the functions of T lymphocytes as well as functions of cells of the innate 
immune system (72). Following published evidence from oncology studies the 
suppressive role of MDSCs in infectious diseases, e.g. HIV, has been 
investigated and established (76-78). In natural untreated HIV infection, 
polymorphonuclear (PMN)-MDSCs directly correlate to markers of disease 
progression namely decreasing CD4 cell count and increasing viral load. ART 
suppressed viral replication leads to a substantial decrease in PMN-MDSC 
levels. PMN-MDSC levels in patients who spontaneously control HIV infection 
were comparable to those of treated patients (76). However, data in SIV-
infected monkeys report higher levels of PMN-MDSC during ART than prior to 
infection (79). 
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Recently, MDSC classification as well as an agreement for minimal criteria of 
the phenotyping were introduced in a consensus paper. Thus, the two major 
subsets are termed and defined PMN-MDSCs with a CD14-, CD11b+, 
CD66b+/CD15+ phenotype, and monocytic (M) MDSCs with a CD11b+, CD14+, 
HLA-DR-/low, CD 15- phenotype (80). The same definitions were used for our 
studies. 
The growing scientific interest in these cells and the fact that MDSCs are a 
vulnerable cell type, resulted in the aim to harmonize methodological 
approaches in MDSC research. We identified MDSC phenotyping and the time 
frame between blood draw and cell processing as well as the recovery after 
freezing as critical in terms of comparing studies in the field. Vollbrecht et al., 
Tumino et al. and Qin et al. found different elevated MDSC subsets in chronic 
HIV infected patients compared to healthy controls. In contrast to elevated 
PMN-MDSC frequencies in chronic HIV infection (Vollbrecht et al. and Tumino 
et al. respectively), Qin et al. found the frequencies of these cells comparable to 
healthy controls (76, 77, 81). One probable explanation for discrepancies in 
study results is the difference in the handling of the cells after blood draw. In 
order to suggest the best time point to analyze frequencies of MDSCs, we 
conducted the first study of this dissertation. Besides the kinetics of cells after 
blood draw, we analyzed the sensitivity of MDSCs to freezing procedures. 
Finding a sterilizing or at least a functional cure for HIV infection is an ultimate 
research goal. Treatment intensification and start of treatment during acute 
infection are strategies with the aim of reaching this goal that is the rationale of 
the second study of this dissertation. We were provided with the unique 
opportunity to evaluate the immunosuppressive cells in the treatment strategy of 
New Era (see chapter 3.1.3) before an intended treatment interruption: It was 
reported that 3ART consisting of three antiretroviral drugs influences the levels 
of immunosuppressive cells (76, 82-85). Thus, PMN-MDSC levels in patients 
with 3ART regimen are decreased (76). Our research objective was, whether an 
ART regimen consisting of 5 drugs intensifies this effect on PMN-MDSCs and 
other immunological markers. 
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3.2.2. Regulatory T cells (Tregs) 
Tregs develop of progenitor T cells in the thymus after the CD8 T cell population 
has differentiated. Phenotypically, Tregs are described to be CD4+, CD25+, and 
FoxP3+. Expressing the CD4 surface marker, Tregs are a target of HIV. 
Ample evidence for the immunosuppression by Tregs in HIV infection can be 
found in the literature (73-75, 82, 86-90). In fact, these cells are the most well-
known immunosuppressive cell type in HIV disease. Tregs act 
immunosuppressively by inhibiting T cell responses resulting in viral 
persistence. However, there are still open questions about their ambivalent role 
in the immune system.  
Tregs are known to reduce immune activation and excessive immune reactions 
(tissue damage) during acute infection (73-75, 86, 88, 90). Given that immune 
activation leads to fast progression in chronic HIV infection (56, 59, 60), this 
would be a beneficial effect of Tregs in HIV infection. However, Cao et al. found 
high Treg levels in parallel to a high proportion of activated T lymphocytes in 
advanced HIV disease which stands for a lack of suppression of immune 
activation (90). During ART, Tregs were found to have the ability to control 
residual immune activation but 12 months after treatment interruption, the cells 
did not control immune activation anymore (82). 
In the course of untreated HIV infection, the absolute number of Tregs 
decreases because of the reduction of CD4 cell counts while the relative 
frequencies increase (73, 74, 82, 86, 88). Successful antiretroviral treatment 
(ART) decreases proportionally Treg frequencies (75, 86, 89) whereas 
treatment interruption results again in increased Treg levels with suppressive 
potential (82). Although Tregs are well-described immune suppressive cells in 
HIV infection, to our knowledge, there is no data of the impact of an intensified 
treatment itself and its start in acute infection on the Treg levels. To fill this gap, 
we analyzed relative and absolute Treg levels in patients of the New Era study 
and compared them to control groups. 
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3.2.3. Regulatory B cells (Bregs) 
Bregs were identified only recently as cells with immune suppressive 
capabilities in HIV infection (reviewed in (73)). For evolvement of Bregs from 
progenitor B cells toll-like receptor (TLR) stimulation is an important promoter 
(71). TLR agonists are products of well-known microbial translocation described 
in HIV infection (83, 91, 92). Phenotypically Bregs are defined as CD19+, 
CD24hi, CD38hi and produce IL-10 which has been shown to inhibit T cell 
function (71, 93). Depletion experiments confirmed the immunosuppressive 
function of Bregs. Breg-depleted peripheral blood mononuclear cells (PBMCs) 
showed augmented proliferation and levels of cytotoxic HIV-specific CD8 T cells 
followed by diminished HIV-infected CD4 T cells. Increased Breg levels have 
been related with a higher viral load, immune activation, and CD8 T cell 
exhaustion (84). Looking at IL10+-Breg frequencies in various patient groups 
and disease stages compared to uninfected subjects, the cells were already 
substantially increased in untreated early infection as well as in chronic HIV-
infected patients without ART and even in patients with ART and in elite 
controller (85). For a more comprehensive evaluation of the immune status of 
the New Era population, we thought it indispensable to include Bregs in our 
studies. At the same time we were able to gain data and a better understanding 
of these cells as relatively newly defined participants in immunosuppressive 













The loss of efficacy of the CD8 T cell response is a crucial process for the 
progression of HIV infection. Despite intense research efforts in the last years, 
the reasons for the so-called immune exhaustion remain elusive. Forefront 
among supposed causes are inhibitory T cell receptors and immunosuppressive 
cells. The aim of this dissertation was to specify the impact of immune 
suppressive cells in chronic HIV infection. 
In our first publication (94), two subsets of MDSCs were analyzed in 42 patients 
with chronic viral infection (n = 25) or with solid tumors (n = 17) to determine the 
best time point (2, 4, 6 hours and overnight rest (ON) respectively) for further 
processing after blood draw as well as freezing properties. Our results show 
that the frequencies of PMN-MDSCs were comparable within 6 hours after 
blood draw (p > 0.5). Whereas frequencies of M-MDSCs were reduced 6 hours 
after blood draw and after ON respectively (2 hours vs. 6 hours after blood draw 
and ON respectively: p < 0.0051). In both subsets frequencies were significantly 
decreased after freezing (PMN-MDSCs: p = 0.0001; M-MDSCs: p = 0.04) and 
we, therefore, recommend to analyze MDSCs in fresh PBMCs only within 6 
hours (PMN-MDSCs) and 4 hours (M-MDSCs) respectively. 
In the second publication (95), we analyzed the frequencies of immune 
suppressive cells (two subsets of MDSCs, Tregs and Bregs) as well as the HIV-
specific CD8 T cell response in the special cohort of patients of the New Era 
study compared to different control groups. The treatment intensification had no 
influence on frequencies of MDSCs and Bregs compared to those of 
conventional 3-drug ART treated patients (p > 0.21). In contrast, the levels of 
Tregs in NE were significantly lower compared to 3ART patients (p < 0.0001) as 
well as to other control groups with HIV-infected patients (p < 0.0033). The CD8 
T cell response in NE was broader (p = 0.0134) with a higher magnitude (p = 
0.026) compared to 3ART patients. This second project was done in 
cooperation with a medical student who worked on part of the project. 
Despite tremendous efforts, neither a sterilizing nor a functional cure in HIV 
infection was achieved in more than 30 years of HIV research. For the 
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persistence of the HI virus, an involvement of immune exhaustion of T cell 
responses is obvious among other factors. For this phenomenon, immune 
suppressive cells are a decisive part of the puzzle. The aim of this dissertation 
was to further elucidate the role of immune suppressive cells in HIV infection 
with the final goal of therapeutical use. We found that MDSCs should be 
analyzed in fresh PBMCs and that Tregs were the only immunosuppressive cell 
type that was significantly reduced by intensified treatment independent of its 
start in acute or chronic infection. However, more research will be needed. 
Recently, we gained evidence that MDSCs lose effector functions in advanced 
HIV disease as already shown for CD8 T cells (96). 
4.2. Deutsche Zusammenfassung 
Ein entscheidender Prozess in der fortschreitenden HIV-Infektion ist der Verlust 
der Effektivität der CD8 T-Zellantwort. Trotz intensiver Forschung in den letzten 
Jahren, sind die Ursachen dieser sogenannten Immunerschöpfung noch nicht 
vollständig geklärt. Dazu gehören u. a. inhibitorische T-Zellrezeptoren und 
immunsuppressive Zellen. Ziel dieser Arbeit war es, die Bedeutung von 
immunsuppressiven Zellen in der chronischen HIV-Infektion näher zu 
bestimmen. 
In unserer ersten Veröffentlichung (94), wurden zwei Subtypen von MDSCs bei 
42 Patienten mit chronischer viraler Infektion (n = 25) oder soliden Tumoren (n 
= 17) hinsichtlich ihrer zeitlichen Weiterverarbeitung 2, 4 und 6 Stunden nach 
Blutentnahme bzw. Inkubation über Nacht (ÜN) sowie der Einfrierbarkeit 
untersucht. Unsere Ergebnisse zeigten, dass die Frequenzen von PMN-MDSCs 
innerhalb von 6 Stunden (p > 0,5) nach Blutentnahme vergleichbar waren. Bei 
M-MDSCs dagegen waren die Frequenzen nach 6 Stunden bzw. ÜN signifikant 
erniedrigt (2 Stunden vs. 6 Stunden nach Blutentnahme bzw. ÜN: p < 0,0051). 
Bei beiden Zelltypen erniedrigten sich die Frequenzen der Zellen nach dem 
Einfrieren signifikant (PMN-MDSCs: p = 0,0001; M-MDSCs: p = 0,04). Deshalb 
empfehlen wir, MDSCs nur aus frischen PBMCs  innerhalb von 4 bzw. 6 
Stunden nach Blutentnahme zu analysieren.  
In der zweiten Veröffentlichung (95), untersuchten wir die Frequenzen von 
immunsuppressiven Zellen (zwei Subtypen MDSCs, Tregs und Bregs) sowie 
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HIV-spezifische CD8 T-Zellantworten bei dem besonderen Patientenkollektiv 
der New Era Studie im Vergleich zu verschiedenen Kontrollgruppen. Die 
Therapieintensivierung hatte keinen Einfluss auf die Frequenzen von MDSCs 
und Bregs im Vergleich zu denen bei Patienten mit konventioneller 3fach-ART 
(p > 0,21). Dagegen waren Tregs bei den NE Patienten signifikant erniedrigt 
sowohl im Vergleich zu 3ART Patienten (p < 0,0001) als auch zu den weiteren 
HIV-infizierten Kontrollgruppen (p < 0,0033). Die CD8 T-Zellantwort der 
Patienten mit Therapieintensivierung war breiter (p = 0,0134) und stärker (p = 
0,026) als bei 3ART Patienten. Dieser zweite Teil der Dissertation wurde in 
Zusammenarbeit mit einer medizinischen Doktorandin durchgeführt, die einen 
Teil der Arbeiten übernahm. 
Trotz 30 Jahre intensiver HIV-Forschung wurde weder eine sterilisierende noch 
eine funktionelle Heilung in der HIV-Infektion erreicht. Zur Persistenz des HI 
Virus trägt, neben anderen Faktoren, die Immunerschöpfung entscheidend bei. 
Bei diesem Phänomen sind immunsuppressive Zellen ein Stück des Puzzles. 
Das Ziel dieser Dissertation war es, die Rolle der immunsuppressiven Zellen in 
der HIV-Infektion weiter aufzuklären mit dem letztendlichen Ziel einer 
therapeutischen Anwendung dieser Zellen. Wir zeigten, dass MDSCs aus 
frischem PBMCs analysiert werden sollen und dass Tregs die einzige 
immunsuppressive Zellsorte war, die durch eine intensivierte Therapie 
signifikant reduziert wurde unabhängig vom Therapiestart in der akuten oder 
chronischen Infektion. Jedoch sind weitere Studien zu diesen Zellen nötig, um 
deren Einsatz therapeutisch zu nutzen. So konnten wir kürzlich nachweisen, 
dass PMN-MDSCs ebenso wie CD8 T Zellen mit Fortschreiten der HIV-Infektion 
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